TECHNETIUM TC 99M MERTIATIDE KIT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Technetium Tc 99m Mertiatide Kit, and what generic alternatives are available?
Technetium Tc 99m Mertiatide Kit is a drug marketed by Jubilant Draximage and is included in one NDA.
The generic ingredient in TECHNETIUM TC 99M MERTIATIDE KIT is technetium tc-99m mertiatide kit. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the technetium tc-99m mertiatide kit profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TECHNETIUM TC 99M MERTIATIDE KIT?
- What are the global sales for TECHNETIUM TC 99M MERTIATIDE KIT?
- What is Average Wholesale Price for TECHNETIUM TC 99M MERTIATIDE KIT?
Summary for TECHNETIUM TC 99M MERTIATIDE KIT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | TECHNETIUM TC 99M MERTIATIDE KIT at DailyMed |
US Patents and Regulatory Information for TECHNETIUM TC 99M MERTIATIDE KIT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jubilant Draximage | TECHNETIUM TC 99M MERTIATIDE KIT | technetium tc-99m mertiatide kit | POWDER;INTRAVENOUS | 216820-001 | Jan 30, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Summary:
The Technetium Tc-99m Mertiatide Kit is a radiopharmaceutical used primarily for cardiac imaging, particularly renal function assessment. Its market is influenced by factors such as increasing demand for nuclear imaging, regulatory approvals, and competition from alternative diagnostic agents. Financially, the product’s trajectory depends on R&D investments, manufacturing capacity, reimbursement policies, and uptake by healthcare providers.
What Are the Market Drivers for Technetium Tc-99m Mertiatide Kit?
The key drivers include rising utilization of nuclear medicine procedures, aging populations with higher prevalence of chronic kidney disease, and the need for accurate, minimally invasive renal imaging agents. The global nuclear medicine market is expected to grow annually at approximately 4-6% between 2022 and 2027 [1].
Regulatory approvals significantly impact market access. For instance, in 2019, the FDA approved additional indications for Tc-99m based renal agents, including Mertiatide, broadening its clinical scope [2].
Advancements in imaging technology and a push for more precise diagnostics favor agents like Mertiatide. However, the scarcity of molybdenum-99 (Mo-99), the parent isotope of Tc-99m, affects supply stability and pricing, influencing market dynamics.
How Does the Competitive Landscape Affect Financial Outcomes?
The market for renal imaging agents includes several radiopharmaceuticals:
- Technetium-99m DTPA
- Technetium-99m MAG3 (Mertiatide)
- Technetium-99m Mercaptoacetyltriglycine (MAG3)
Mertiatide is often preferred over DTPA due to better renal extraction efficiency, resulting in clearer imaging. It faces competition mainly from these agents, but its clinical advantages help maintain market share.
Generic versions and biosimilar development pose a threat to revenue streams. Patent protections typically last 7-12 years from approval, with some variations depending on jurisdiction. Patent expirations for similar agents begin occurring around 2025, pressuring pricing and margins.
Market players like Curium and Lantheus hold significant portions of the radiopharmaceutical market. Establishing manufacturing capacity for Mo-99 and securing supply agreements are crucial to sustain revenues.
What Are the Regulatory and Supply Chain Impacts on Financial Trajectory?
Supply chain stability for Tc-99m, derived from Mo-99, directly impacts sales. Mo-99 supply constraints existed in 2018-2019, leading to shortages and increased prices, which temporarily disrupted sales volumes [3].
Recent efforts to develop alternative production methods, including non-reactor sources, aim to stabilize supply. Countries like Australia and Canada have increased production capacity, reducing the dependency on aging reactors in Europe and North America [4].
Regulatory environments can either facilitate or hinder market access. Enhanced focus on reducing radiation exposure and improving imaging quality may lead to new approval pathways, influencing the product’s financial trajectory.
What Are the Revenue and Investment Trends?
The global nuclear medicine market, valued at approximately $6 billion in 2021, is projected to reach $8.5 billion by 2027, with radiopharmaceuticals accounting for a significant share [1].
Specific to Mertiatide, revenue streams depend on unit sales volume, pricing strategies, and reimbursement rates. Reimbursement for renal scans using Tc-99m agents remains stable in key markets like the U.S., supported by CMS (Centers for Medicare & Medicaid Services).
R&D efforts focus on developing next-generation agents with better targeting and lower radiation doses, potentially creating new revenue opportunities or replacing existing products.
Investments from pharmaceutical companies continue to support production capacity increases and pipeline expansion. The focus on improving stability and supply chain resilience adds to capital expenditure trends.
What Is the Future Outlook for Market and Financial Performance?
The outlook remains positive, driven by broader adoption of nuclear imaging. The growth rate for Tc-99m based agents will largely follow the overall nuclear medicine industry trends.
Potential market expansion occurs through new indications, improving imaging technologies, and geographic penetration, notably in emerging markets where healthcare infrastructure is expanding.
However, price competition, patent expirations, and supply chain vulnerabilities could temper growth, requiring firms to adapt operational strategies.
Investors should monitor regulatory changes, Mo-99 production developments, and competitor movements to assess long-term viability.
Key Takeaways
- Market growth is driven by increased demand for nuclear imaging and demographic trends; projected CAGR of 4-6% (2022-2027).
- Competition from other Tc-99m agents and biosimilars influences pricing and market share.
- Supply chain stability for Mo-99 and regulatory frameworks significantly shape revenue potential.
- Strategic investment in manufacturing capacity and pipeline expansion sustains financial performance amid supply constraints.
- Future growth depends on technological advancements, geographic expansion, and regulatory approvals.
FAQs
More… ↓
